DF/HCC Program Affiliation

DF/HCC Associations

Research Abstract

Publications

• Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL,.Efficacy of letrozole extended adjuvant therapy accor
  17452676
• Moy B, Goss PE.TEACH: Tykerb evaluation after chemotherapy.Clin Breast Cancer 2007 Feb;7(6):489-92.
  17386127
• Booth CM, Pater JL, Goss PE.Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen.Cancer 2007 May 1;109(9):1927-8; author reply 1928.
  17354227
• Goss PE, Strasser-Weippl K, Qi S, Hu H.Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-induced mammary carcinoma and uterus in the rat model.BMC Cancer 2007;7:26.
  17266767
• Vachon CM, Ingle JN, Suman VJ, Scott CG, Gottardt H, Olson JE, Goss PE.Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen.Breast 2007 Apr;16(2):204-10.
  17145182
• Chien AJ, Goss PE.Aromatase inhibitors and bone health in women with breast cancer.J Clin Oncol 2006 Nov 20;24(33):5305-12.
  17114665
• Moy B, Goss PE.Lapatinib: current status and future directions in breast cancer.Oncologist 2006 Nov-Dec;11(10):1047-57.
  17110623
• Moy B, Tu D, Pater JL, Ingle JN, Shepherd LE, Whelan TJ, Goss PE.Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer.Ann Oncol 2006 Nov;17(11):1637-43.
  16936184
• Moy B, Goss PE.Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches.Clin Cancer Res 2006 Aug 15;12(16):4790-3.
  16914563
• Ryan PD, Goss PE.Adjuvant hormonal therapy in peri- and postmenopausal breast cancer.Oncologist 2006 Jul;11(7):718-31.
  16880231
• Delea TE, Karnon J, Goss PE.Conclusions regarding relative cost-utility of alternative strategies for use of aromatase inhibitors in postmenopausal women with early breast cancer are premature.Ann Oncol 2006 Jul 27.
  16873429
• Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE.Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more year
  16822845
• Goss PE.Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.Semin Oncol 2006 Apr;33(2 Suppl 7):S8-12.
  16730271
• Cigler T, Goss PE.Aromatase inhibitor withdrawal response in metastatic breast cancer.J Clin Oncol 2006 Apr 20;24(12):1955-6.
  16622274
• Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE.Duration of letrozole treatment and outcomes in the pl
  16541302
• Karnon J, Delea T, Johnston SR, Smith R, Brandman J, Sung J, Goss PE.Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective.Pharmacoeconomics 2006;24(3):237-50.
  16519546
• Goss PE, Qi S, Cheung AM, Hu H, Mendes M, Pritzker KP.The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats.J Steroid Biochem Mol Biol 2004
  15544933
• Goss PE, Qi S, Josse RG, Pritzker KP, Mendes M, Hu H, Waldman SD, Grynpas MD.The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats.Bone 2004 Mar;34(3):384-92.
  15003786
• Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL.A randomized trial of letrozole in postmenopausal wome
  14551341
• Ma XJ, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V, Harris A, Goss P, Sotiriou C, Erlander M, Sgroi D.A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer.Clin Cancer Res 2008 May 1;14(
  18451222
• Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E.Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the
  18378608
• Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu D.Late extended adjuvant treatment with letrozole improv
  18332475
• Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan TJ, Palmer MJ, Piccart MJ, Shepherd LE, Pritchard KI, He Z, Goss PE.Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo aft
  18332474
• Chapman JA, Meng D, Shepherd L, Parulekar W, Ingle JN, Muss HB, Palmer M, Yu C, Goss PE.Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer.Journal of the National Cancer Institute 2008 Feb 20;100(4):
  18270335
• Goss PE, Richardson H, Chlebowski R, Johnston D, Sarto GE, Maunsell E, Ingle JN, Ales-Martinez JE.National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women.Clin Breast
  18269782
• Ryan PD, Goss PE.The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer.Oncologist 2008 Jan;13(1):16-24.
  18245009
• Buzdar AU, Coombes RC, Goss PE, Winer EP.Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer.Cancer 2008 Feb 1;112(3 Suppl):700-9.
  18072256
• Come SE, Buzdar AU, Ingle JN, Johnston SR, Brodie AM, Coombes RC, Miller WR, Pritchard KI, Winer EP, Zujewski JA, Goss PE.Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.Cancer 2008 Feb 1;112(3 Su
  18072254
• Gligorov J, Pritchard K, Goss P.Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis.Breast 2007 Dec;16 Suppl 3:S1-9.
  18061455
• Goss PE.Letrozole in the extended adjuvant setting: MA.17.Breast Cancer Res Treat 2007;105 Suppl 1:45-53.
  17912635
• Goss P, Bondarenko IN, Manikhas GN, Pendergrass KB, Miller WH Jr, Langecker P, Blanchett D.Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cance
  17971594
• Wu M, Goss PE.Update on the use of letrozole in breast cancer.Expert Opin Pharmacother 2007 Oct;8(14):2329-45.
  17927487
• Goss P, Wu M.Application of aromatase inhibitors in endocrine responsive breast cancers.Breast 2007 Dec;16 Suppl 2:S114-9.
  17719783
• Moy B, Goss PE.Lapatinib-associated toxicity and practical management recommendations.Oncologist 2007 Jul;12(7):756-65.
  17673607
• Goss P, von Eichel L.Summary of aromatase inhibitor trials: the past and future.J Steroid Biochem Mol Biol 2007 Aug-Sep;106(1-5):40-8.
  17627816
• Santen RJ, Demers L, Ohorodnik S, Settlage J, Langecker P, Blanchett D, Goss PE, Wang S.Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy.Steroids 2007 Jul;72(8):666-71.
  17588628
• Pater J, Tu D, Shepherd L, Ingle JN, Goss PE.Decision making in adjuvant trials in breast cancer: the NCIC CTG MA.17 trial as an example.Breast Cancer Res Treat 2007 May 3.
  17476587
• del Carmen MG, Halpern EF, Kopans DB, Moy B, Moore RH, Goss PE, Hughes KS.Mammographic breast density and race.AJR Am J Roentgenol 2007 Apr;188(4):1147-50.
  17377060
• Goss PE, Qi S, Hu H, Cheung AM.The effects of atamestane and toremifene alone and in combination compared with letrozole on bone, serum lipids and the uterus in an ovariectomized rat model.Breast Cancer Res Treat 2006 Oct 25.
  17063268
• Pritchard KI, Goss PE, Shepherd L.The extended adjuvant NCIC CTG MA.17 trials: initial and rerandomization studies.Breast 2006 Feb;15 Suppl 1:S14-20.
  16500236
• Ryan PD, Goss PE.The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer.Nat Clin Pract Oncol 2005 Dec;2(12):596-7.
  16341095
• Suen TC, Tang MS, Goss PE.Model of transcriptional regulation of the BRCA1-NBR2 bi-directional transcriptional unit.Biochim Biophys Acta 2005 May 1;1728(3):126-34.
  15777733
• Strasser-Weippl K, Goss PE.Advances in adjuvant hormonal therapy for postmenopausal women.J Clin Oncol 2005 Mar 10;23(8):1751-9.
  15755983